Related Experiment Videos
Abnormal alpha-synuclein interactions with rab3a and rabphilin in diffuse Lewy body disease
E Dalfó1, M Barrachina, J L Rosa
1Unitat de Bioquímica, Departament de Ciències Fisiològiques II, Campus de Bellvitge, Universitat de Barcelona, Hospitalet de Llobregat, Barcelona, Spain.
Neurobiology of Disease
|June 23, 2004
Summary
Alpha-synuclein interactions with rab3a and rabphilin change in Lewy body disease (LBD). Binding decreases between rab3a and rabphilin, but increases between rab3a and alpha-synuclein aggregates, potentially impairing neurotransmitter release.
Area of Science:
- Neuroscience
- Molecular Biology
- Pathology
Background:
- Alpha-synuclein aggregation is a hallmark of Lewy body disease (LBD).
- Rab3a and rabphilin are key proteins involved in synaptic vesicle trafficking.
- The precise molecular interactions of these proteins in LBD remain incompletely understood.
Purpose of the Study:
- To investigate the interactions between alpha-synuclein, rab3a, and rabphilin in the entorhinal cortex of control and LBD cases.
- To elucidate how these interactions are altered in the pathological context of LBD.
Main Methods:
- Utilized antibody arrays, immunoprecipitation, and pull-down assays.
- Examined protein binding patterns in brain tissue from control and LBD subjects.
- Employed His(6)/Flag-tagged proteins for in vitro interaction studies.
Main Results:
- Alpha-synuclein bound to rabphilin in controls, but not in LBD cases.
- Rab3a bound to rabphilin in controls, but not in LBD cases.
- Rab3a interacted with high molecular weight alpha-synuclein aggregates specifically in LBD cases.
Conclusions:
- Findings indicate decreased rab3a-rabphilin binding and increased rab3a-alpha-synuclein aggregate binding in LBD.
- Altered interactions suggest potential impairment of synaptic vesicle exocytosis and neurotransmitter release in LBD.
- These molecular changes may contribute to the pathophysiology of LBD.